← Back

Wire · operational-macro

Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non ...

Published

17 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at us.gsk.com →

◆ Verified

Fusion42 · 17 November 2026 · Fusion42 review

The US FDA has granted accelerated approval to Nelkarmi (neladalkib) for adults with previously treated advanced ALK-positive non-small cell lung cancer, based on the ALKOVE-1 trial demonstrating meaningful and durable responses. Nelkarmi is designed to address treatment resistance and brain metastases with improved tolerability, marking GSK's second lung cancer drug approval this year.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

Your lung cancer drug portfolio just gained a new competitor that handles resistant and brain metastasis cases better. If you work on ALK-positive NSCLC treatments, prepare for tougher differentiation and faster patient access to advanced therapies.

◆ Coverage

2 sources · 17 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvallung-canceralk-inhibitorgskoncologydrug-resistance